FTC Tells High Court Impax Ruling Needs No Review
The U.S. Supreme Court should reject Impax Laboratories' bid to review a Fifth Circuit decision that found the generics maker ran afoul of antitrust laws by cutting a deal with Endo...To view the full article, register now.
Already a subscriber? Click here to view full article